Timolat is a non-selective beta adrenergic blocking agent, supplied as a sterile isotonic buffered aqueous solution of Timolol Maleate.

Ophthalmic solution is indicated in the treatment of elevated intraocular pressure with ocular hypertension associated with open angle glaucoma and aphakic glaucoma.

The usual starting dose is one drop of 0.25% Timolat in affected eyes twice a day. If the clinical response is not adequate the dose may be changed to one drop of 0.5% solution in the affected eyes twice a day. If necessary the physician may institute a concomitant therapy: Systemically administered carbonic anhydrase inhibitor, in order to obtain a better response. But concomitant use of two topical beta adrenergic blocking agents is not recommended. Since in some patients the pressure lowering response to Timolat may require a few weeks to stabilize. If IOP is maintained at satisfactory levels, the dosage schedule may be changed to one drop once a day in affected eyes.

Timolat is contraindicated in patients with bronchial asthma, a history of bronchial asthma, severe chronic obstructive pulmonary diseases, sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, cardiogenic shock or hypersensitivity to any component of this product.

These agents should be used with caution in patients with cerebro vascular insufficiency. Timolol Maleate has little or no effect on the pupil, so Timolat should not be used alone in treatment of angle closure glaucoma because in this case immediate objective is to reopen the angle which requires constricting the pupil.

The most frequently reported adverse experiences have been burning and stinging upon instillation.

Pregnancy category C. Teratogenicity studies with Timolol in mice, rats and rabbits at oral dosage upto 50 mg/kg/day (7000 times the systemic exposure following the maximum recommended human ophthalmic dose) demonstrated to evidence of fetal malformations. Nursing mother: A decision should be made whether to discontinue nursing or to discontinue the drug. Because Timolol Maleate has been detected in human milk following ophthalmic administration.

Drug interaction studies have not been conducted with Romycin (Azithromycin) Eye Drops.

No toxic side effects from systemic overdose are expected.

Store in a cool and dry place, away from light. Keep out of reach of children.

Timolat eye drops: Dropper bottle contains 5 ml drops.